Top

Published in:

01-02-2021 | Peritonectomy | Original Article

Clinical and predictive value of blood lactate levels during cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC): a comparative analysis

Authors: Marco Tonello, Andrea Barina, Federica Turchet, Ottavia De Simoni, Rita Alfieri, Boris Franzato, Mario Gruppo, Bruno Dengo, Davide Deffenu, Daniele Di Pasquale, Tania Fiore, Claudia Pietropaoli, Susanna Munaron, Giorgio Zanardo, Antonio Sommariva, Pierluigi Pilati

Published in: Updates in Surgery | Issue 1/2021

Abstract

Postoperative outcome after cytoreductive surgery followed by hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) is strongly related to surgical and anesthesiologic expertise. This study aims to evaluate the clinical significance and prognostic value of lactate levels (LL) measured during CRS-HIPEC on postoperative outcome compared to similar major surgical procedures. Patients who were treated between January and September 2019 at our Institute and met the inclusion criteria were selected. Patients were divided into three groups: group 1: patients who underwent major surgical procedures; group 2: patients who underwent CRS without HIPEC; group 3: patients who underwent CRS with HIPEC. Intraoperative LL were analyzed and correlated with surgical procedure and postoperative outcome. We observed a significant increase of LL during surgical/CRS phase (group 1: p = 0.0001; group 2: p = 0.001; group 3: p = 0.057), rather than during the HIPEC phase in group 3 (p = ns). In patients undergoing CRS and peritonectomies, the mean LL were significantly higher compared to group 1 (p = 0.05). Although not statistically significant, the complication rate was higher in patients with end-CRS lactate values > 2 mMol/l, especially in the group undergoing CRS plus HIPEC. Our pilot study shows that higher LL during peritoneal cancer surgery are expected compared to major surgical procedures. Cytoreductive phase, rather than HIPEC, is related to an increase of LL. The role of LL as an early marker of postoperative complications after CRS-HIPEC should be further verified in properly designed studies.

Sadeghi B, Arvieux C, Glehen O et al (2000) Peritoneal carcinomatosis from non-gynecologic malignancies: results of the EVOCAPE 1 multicentric prospective study. Cancer 88:358–363CrossRefPubMed

Jayne DG, Fook S, Loi C et al (2002) Peritoneal carcinomatosis from colorectal cancer. Br J Surg 89:1545–1550CrossRefPubMed

Sommariva A, Pilati P, Rossi CR (2012) Cyto-reductive surgery combined with hyperthermic intra-peritoneal chemotherapy for peritoneal surface malignancies: current treatment and results. Cancer Treat Rev 38(4):258–268. https://doi.org/10.1016/j.ctrv.2011.07.001CrossRefPubMed

Sugarbaker PH (1995) Peritonectomy procedures. Ann Surg 221:29–42CrossRefPubMedPubMedCentral

Delhorme JB, Severac F, Averous G, Glehen O, Passot G, Bakrin N, Marchal F, Pocard M, Lo Dico R, Eveno C, Carrere S, Sgarbura O, Quenet F, Ferron G, Goéré D, Brigand C, French National Network of Peritoneal Surface Malignancies (RENAPE) (2018) Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei of appendicular and extra-appendicular origin. Br J Surg 105:668–676

Baratti D, Kusamura S, Cabras AD, Bertulli R, Hutanu I, Deraco M (2013) Diffuse malignant peritoneal mesothelioma: long-term survival with complete cytoreductive surgery followed by hyperthermic intraperitoneal chemotherapy (HIPEC). Eur J Cancer 49(15):3140–3148. https://doi.org/10.1016/j.ejca.2013.05.027CrossRefPubMed

Klaver CE, Groenen H, Morton DG, Laurberg S, Bemelman WA, Tanis PJ, Research Committee of the European Society of Coloproctology (2017) Recommendations and consensus on the treatment of peritoneal metastases of colorectal origin: a systematic review of national and international guidelines. Colorectal Dis 19(3):224–236

van Driel WJ, Koole SN, Sikorska K et al (2018) Hyperthermic intraperitoneal chemotherapy in ovarian cancer. N Engl J Med 378(3):230–240. https://doi.org/10.1056/NEJMoa1708618CrossRefPubMed

Chua TC, Yan TD, Saxena A, Morris DL (2009) Should the treatment of peritoneal carcinomatosis by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy still be regarded as a highly morbid procedure? A systematic review of morbidity and mortality. Ann Surg 249(6):900–907CrossRefPubMed

10.

Foster JM, Sleightholm R, Patel A et al (2019) Morbidity and mortality rates following cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy compared with other high-risk surgical oncology procedures. JAMA Netw Open 2(1):e186847. https://doi.org/10.1001/jamanetworkopen.2018.6847 ((Published 2019 Jan 4))CrossRefPubMedPubMedCentral

11.

Leigh NL, Solomon D, Feingold D et al (2020) Improved survival with experience: a 10-year learning curve in hyperthermic intraperitoneal chemotherapy and cytoreductive surgery. Ann Surg Oncol 27(1):222–231. https://doi.org/10.1245/s10434-019-07518-1CrossRefPubMed

12.

Raspe C, Piso P, Wiesenack C, Bucher M (2012) Anesthetic management in patients undergoing hyperthermic chemotherapy. Curr Opin Anaesthesiol 25(3):348–355. https://doi.org/10.1097/ACO.0b013e32835347b2CrossRefPubMed

13.

Vincent JL, Quintairos E Silva A, Couto L Jr., Taccone FS (2016) The value of blood lactate kinetics in critically ill patients: a systematic review. Crit Care 20(1):257. https://doi.org/10.1186/s13054-016-1403-5(Published 2016 Aug 13)

14.

Dindo D, Demartines N, Clavien PA (2004) Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 240:205–213CrossRefPubMedPubMedCentral

15.

González-Moreno S, Kusamura S, Baratti D et al (2008) Postoperative residual disease evaluation in the locoregional treatment of peritoneal surface malignancy. J Surg Oncol 98:237–241CrossRefPubMed

16.

Portilla AG, Shigeki K, Dario B et al (2008) The intraoperative staging systems in the management of peritoneal surface malignancy. J Surg Oncol 98:228–231CrossRefPubMed

17.

Sommariva A, Tonello M, Cona C, Pilati P, Rossi CR (2018) Iterative cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent peritoneal metastases. Anticancer Res 38(9):5521–5524. https://doi.org/10.21873/anticanres.12886CrossRefPubMed

18.

Colantonio L, Claroni C, Fabrizi L, Marcelli ME, Sofra M, Giannarelli D et al (2015) A randomized trial of goal directed vs. standard fluid therapy in cytoreductive surgery with hyperthermic intraperitoneal chemotherapy. J Gastrointest Surg 19:722–729

19.

Raue W, Tsilimparis N, Bloch A, Menenakos C, Hartmann J (2009) Volume therapy and cardiocircular function during hyperthermic intraperitoneal chemotherapy. Eur Surg Res 43:365–372CrossRefPubMed

20.

Miao N, Pingpank JF, Alexander HR, Royal R, Steinberg SM, Quezado MM et al (2009) Cytoreductive surgery and continuous hyperthermic peritoneal perfusion in patients with mesothelioma and peritoneal carcinomatosis: hemodynamic, metabolic, and anesthetic considerations. Ann Surg Oncol 16:334–344CrossRefPubMed

21.

Esquivel J, Angulo F, Bland RK, Stephens AD, Sugarbaker PH (2000) Hemodynamic, cardiac function parameters during heated intraoperative intraperitoneal chemotherapy using the open coliseum technique. Ann Surg Oncol 7(4):296–300CrossRefPubMed

22.

Schmidt C, Creutzenberg M, Piso P, Hobbhahn J, Bucher M (2008) Peri-operative anaesthetic management of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy. Anaesthesia 63(4):389–395. https://doi.org/10.1111/j.1365-2044.2007.05380.xCrossRefPubMed

23.

Okorie N, Dellinger RP (2011) Lactate: biomarker and potential therapeutic target. Crit Care Clin 27:299–326CrossRefPubMed

24.

Fuller BM, Dellinger RP (2012) Lactate as a hemodynamic marker in the critically ill. Curr Opin Crit Care 18(3):267–272CrossRefPubMedPubMedCentral

25.

Lu J, Tan M, Cai Q (2015) The Warburg effect in tumor progression: mitochondrial oxidative metabolism as an anti-metastasis mechanism. Cancer Lett 356(2 Pt A):156–164

26.

aneba CA, Bellance N, Yang L, Pabst L, Nagrath D (2012) Pyruvate uptake is increased in highly invasive ovarian cancer cells under anoikis conditions for anaplerosis, mitochondrial function, and migration. Am J Physiol Endocrinol Metab 303(8):E1036–E1052

27.

Taura P, Lopez A, Lacy AM et al (1998) Prolonged pneumoperitoneum at 15 mmHg causes lactic acidosis. Surg Endosc 12(3):198–201. https://doi.org/10.1007/s004649900633CrossRefPubMed

28.

De Somer F, Ceelen W, Delanghe J et al (2008) Severe hyponatremia, hyperglycemia, and hyperlactatemia are associated with intraoperative hyperthermic intraperitoneal chemoperfusion with oxaliplatin. Perit Dial Int 28(1):61–66CrossRefPubMed

29.

Barfod C, Lundstrøm LH, Lauritzen MM, Danker JK, Sölétormos G, Forberg JL, Berlac PA, Lippert FK, Antonsen K (2015) Peripheral venous lactate at admission is associated with in-hospital mortality, a prospective cohort study. Lange KH Acta Anaesthesiol Scand 59(4):514–523CrossRefPubMed

30.

Creagh-Brown BC, De Silva AP, Ferrando-Vivas P, Harrison DA (2016) Relationship between peak lactate and patient outcome following high-risk gastrointestinal surgery: influence of the nature of their surgery: elective versus emergency. Crit Care Med 44(5):918–925CrossRefPubMed

31.

Cobianchi L, Peloso A, Filisetti C, Mojoli F, Sciutti F (2016) Serum lactate level as a useful predictor of clinical outcome after surgery: an unfulfilled potential? J Thorac Dis 8(5):E295–E297. https://doi.org/10.21037/jtd.2016.03.61CrossRefPubMedPubMedCentral

32.

Spiliotis J, Halkia E, Zouridis A, Vassiliadou D, Zakka M, Kalantzi N, Vaxevanidou A, Pagoulatou A, Vaos N, Efstathiou E, Datsis A (2015) Serum lactate as predictor of morbidity, mortality and long term survival in patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Case Stud Surg. https://doi.org/10.5430/css.v1n1p41CrossRef

Title: Clinical and predictive value of blood lactate levels during cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC): a comparative analysis
Authors: Marco Tonello
Andrea Barina
Federica Turchet
Ottavia De Simoni
Rita Alfieri
Boris Franzato
Mario Gruppo
Bruno Dengo
Davide Deffenu
Daniele Di Pasquale
Tania Fiore
Claudia Pietropaoli
Susanna Munaron
Giorgio Zanardo
Antonio Sommariva
Pierluigi Pilati
Publication date: 01-02-2021
Publisher: Springer International Publishing
Keywords: Peritonectomy
Cytostatic Therapy
Published in: Updates in Surgery / Issue 1/2021
Print ISSN: 2038-131X
Electronic ISSN: 2038-3312
DOI: https://doi.org/10.1007/s13304-020-00908-1

At a glance: The STEP trials

Springer Medicine

Clinical and predictive value of blood lactate levels during cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC): a comparative analysis

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2021

Gut microbiota and colorectal surgery

Laparoscopic segmental resection for tumours of the Angle of Treitz: a challenging but feasible surgical option. Results from a retrospective case-series analysis

Enhanced recovery after surgery in colon and rectal surgery: identification of predictive variables of failure in a monocentric series including 733 patients

Response to: “Multidisciplinary treatment of cancer”

Infectious complications of extra-peritoneal pelvic packing in emergency room

ERAS pathway in colorectal surgery: structured implementation program and high adherence for improved outcomes